Evidence map›Paper›PMID 41716483›Full record

ArticleContemporary clinical trials communications2026

Pharmacokinetics, safety and preliminary efficacy study of montelukast in critically ill infants with developing bronchopulmonary dysplasia (PRISM).

Jason E Lang, Daniel Gonzalez, Chi D Hornik, Rachel Greenberg, Michael O'Shea, Daniel K Benjamin, Karen Chiswell, Sophia Waymers, Matthew Laughon

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Contemporary clinical trials communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jason E LangDepartment of Pediatrics, Duke University School of Medicine, Durham, NC, USA.
Daniel GonzalezDuke Clinical Research Institute, Durham, NC, USA.
Chi D HornikDepartment of Pediatrics, Duke University School of Medicine, Durham, NC, USA.
Rachel GreenbergDepartment of Pediatrics, Duke University School of Medicine, Durham, NC, USA.
Michael O'SheaDepartment of Pediatrics, UNC School of Medicine, The University of North Carolina-Chapel Hill, Chapel Hill, NC, USA.
Daniel K BenjaminDepartment of Pediatrics, Duke University School of Medicine, Durham, NC, USA.
Karen ChiswellDuke Clinical Research Institute, Durham, NC, USA.
Sophia WaymersDuke Clinical Research Institute, Durham, NC, USA.
Matthew LaughonDepartment of Pediatrics, UNC School of Medicine, The University of North Carolina-Chapel Hill, Chapel Hill, NC, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bronchopulmonary dysplasia (BPD) is an inflammatory disease stemming from premature birth and iatrogenic lung injury. BPD is relatively common and frequently fatal; despite this, there are no FDA-approved therapies. Montelukast is increasingly used to treat developing BPD despite scant safety and efficacy data. Infants with developing BPD have high levels of inflammatory leukotrienes; montelukast blocks the cysteinyl leukotriene receptor. Montelukast shows promise due to results from several small BPD studies. For this

Indexed as

Bronchopulmonary dysplasiaMontelukastPrematurity

Identifiers

PMID41716483
PMCPMC12915198

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.